265 related articles for article (PubMed ID: 36739404)
1. Development and verification of a 7-lncRNA prognostic model based on tumor immunity for patients with ovarian cancer.
Feng J; Yu Y; Yin W; Qian S
J Ovarian Res; 2023 Feb; 16(1):31. PubMed ID: 36739404
[TBL] [Abstract][Full Text] [Related]
2. Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer.
Song Y; Qu H
BMC Cancer; 2022 Jun; 22(1):633. PubMed ID: 35676619
[TBL] [Abstract][Full Text] [Related]
3. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer.
Luan L; Dai Y; Shen T; Yang C; Chen Z; Liu S; Jia J; Li Z; Fang S; Qiu H; Cheng X; Yang Z
Front Immunol; 2022; 13():951455. PubMed ID: 36189298
[TBL] [Abstract][Full Text] [Related]
4. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.
Peng Y; Wang H; Huang Q; Wu J; Zhang M
J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063
[TBL] [Abstract][Full Text] [Related]
5. Cuproptosis-related lncRNA signature as a prognostic tool and therapeutic target in diffuse large B cell lymphoma.
Bai X; Lu F; Li S; Zhao Z; Wang N; Zhao Y; Ma G; Zhang F; Su X; Wang D; Ye J; Li P; Ji C
Sci Rep; 2024 Jun; 14(1):12926. PubMed ID: 38839842
[TBL] [Abstract][Full Text] [Related]
6. Molecular Characterization of Cuproptosis-related lncRNAs: Defining Molecular Subtypes and a Prognostic Signature of Ovarian Cancer.
Li N; Yu K; Huang D; Li S; Zeng D; Li J; Fan L
Biol Trace Elem Res; 2024 Apr; 202(4):1428-1445. PubMed ID: 37528285
[TBL] [Abstract][Full Text] [Related]
7. An exosome-derived lncRNA signature identified by machine learning associated with prognosis and biomarkers for immunotherapy in ovarian cancer.
Cui Y; Zhang W; Lu W; Feng Y; Wu X; Zhuo Z; Zhang D; Zhang Y
Front Immunol; 2024; 15():1228235. PubMed ID: 38404588
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analyses of mitophagy-related genes and mitophagy-related lncRNAs for patients with ovarian cancer.
Zheng J; Jiang S; Lin X; Wang H; Liu L; Cai X; Sun Y
BMC Womens Health; 2024 Jan; 24(1):37. PubMed ID: 38218807
[TBL] [Abstract][Full Text] [Related]
9. A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs.
Zhao Q; Fan C
BMC Med Genet; 2019 Jun; 20(1):103. PubMed ID: 31182053
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analyses of glycolysis-related lncRNAs for ovarian cancer patients.
Zheng J; Guo J; Zhu L; Zhou Y; Tong J
J Ovarian Res; 2021 Sep; 14(1):124. PubMed ID: 34560889
[TBL] [Abstract][Full Text] [Related]
11. Construction of Competitive Endogenous RNA Network and Verification of 3-Key LncRNA Signature Associated With Distant Metastasis and Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma.
Su Y; Zhang T; Tang J; Zhang L; Fan S; Zhou J; Liang C
Front Oncol; 2021; 11():640150. PubMed ID: 33869028
[TBL] [Abstract][Full Text] [Related]
12. Integrating multiple machine learning algorithms for prognostic prediction of gastric cancer based on immune-related lncRNAs.
Li G; Huo D; Guo N; Li Y; Ma H; Liu L; Xie H; Zhang D; Qu B; Chen X
Front Genet; 2023; 14():1106724. PubMed ID: 37082204
[No Abstract] [Full Text] [Related]
13. Construction of a Ferroptosis-Related Nine-lncRNA Signature for Predicting Prognosis and Immune Response in Hepatocellular Carcinoma.
Xu Z; Peng B; Liang Q; Chen X; Cai Y; Zeng S; Gao K; Wang X; Yi Q; Gong Z; Yan Y
Front Immunol; 2021; 12():719175. PubMed ID: 34603293
[TBL] [Abstract][Full Text] [Related]
14. Identification and validation of lncRNAs involved in m6A regulation for patients with ovarian cancer.
Zheng J; Guo J; Cao B; Zhou Y; Tong J
Cancer Cell Int; 2021 Jul; 21(1):363. PubMed ID: 34238292
[TBL] [Abstract][Full Text] [Related]
15. Identification and Validation of a Novel Immune-Related Four-lncRNA Signature for Lung Adenocarcinoma.
Wang J; Yin X; Zhang YQ; Ji X
Front Genet; 2021; 12():639254. PubMed ID: 33708243
[TBL] [Abstract][Full Text] [Related]
16. Development and Validation of a Novel Ferroptosis-Related LncRNA Signature for Predicting Prognosis and the Immune Landscape Features in Uveal Melanoma.
Ma X; Yu S; Zhao B; Bai W; Cui Y; Ni J; Lyu Q; Zhao J
Front Immunol; 2022; 13():922315. PubMed ID: 35774794
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
18. Identification and validation of endocrine resistance-related and immune-related long non-coding RNA (lncRNA) signatures for predicting endocrinotherapy response and prognosis in breast cancer.
Yang M; Sun Y; Ji H; Zhang Q
Ann Transl Med; 2022 Dec; 10(24):1399. PubMed ID: 36660659
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of immune-related gene signature based on ssGSEA algorithms in the prognosis and immune landscape of hepatocellular carcinoma.
Wang L; Wang L; He P
Front Genet; 2022; 13():1064432. PubMed ID: 36568383
[No Abstract] [Full Text] [Related]
20. A signature based on anoikis-related genes for the evaluation of prognosis, immunoinfiltration, mutation, and therapeutic response in ovarian cancer.
Duan Y; Xu X
Front Endocrinol (Lausanne); 2023; 14():1193622. PubMed ID: 37383389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
